Australian Court Ruling Opens Entresto to Generic Competition, Invalidates Novartis Patent Extension
核心洞察
The Full Court of the Federal Court of Australia unanimously dismissed Novartis' appeal, upholding that Pharmacor (搜索)'s generic sacubitril/valsartan products do not infringe Novartis' composition patent for Entresto.
The court ruled that Novartis' patent term extension was wrongly granted, with the patent expiring in January 2023, three months before generic registrations.
Generic sacubitril/valsartan products from Pharmacor (搜索) and Apotex (搜索) have now received PBS listing in Australia, opening the market to competition against Novartis' blockbuster heart failure drug.
The Full Court of the Federal Court of Australia has delivered a decisive blow to Novartis' patent protection for its blockbuster heart failure drug Entresto, unanimously dismissing the company's appeal and clearing the way for generic competition in the Australian market.
In a March 2025 ruling, Justices Burley, Rofe and Downes upheld Justice Yates' November 2024 decision that found Pharmacor (搜索)'s generic sacubitril/valsartan products do not infringe Novartis' composition patent AU2003206738. The court also confirmed that Novartis' patent term extension (PTE) was wrongly granted, effectively ending patent protection on January 16, 2023.
Patent Construction Determines Market Access
The central issue in the case hinged on the proper construction of claim 1 of Novartis' patent, which covers pharmaceutical compositions comprising valsartan (an AT1-antagonist), sacubitril or sacubitrilat (NEP inhibitors), and a pharmaceutically acceptable carrier for treating hypertension, heart failure, and myocardial infarction.
The Full Court rejected Novartis' argument that the patent claim covered any pharmaceutical composition delivering valsartan and sacubitril as active ingredients, regardless of their chemical bonding. Instead, the court determined that claim 1 required distinct and separate components, not a single chemical complex.
"The conjunction 'and' between integers (i) and (ii) indicated that there must be both the AT1-antagonist of integer (i) and also the NEP sacubitril/at of integer (ii) in the composition, as distinct and separate components," the court ruled.
Generic Products Fall Outside Patent Scope
The court's construction analysis proved determinative for both infringement and patent validity questions. Pharmacor (搜索)'s generic sacubitril/valsartan product contains a single chemical entity consisting of sacubitril, valsartan and sodium associated by non-covalent bonds, which the court found did not infringe the patent.
Significantly, the court also determined that Novartis' own Entresto formulation - a film-coated tablet containing a salt complex of anionic forms of sacubitril and valsartan with sodium cations and water molecules - did not actually fall within the scope of its own patent claims. This finding invalidated the patent term extension, which had been based on Entresto's ARTG registration.
Expert Evidence Supports Court's Interpretation
Expert witnesses agreed that the patent's composition required two active pharmaceutical ingredients or their pharmaceutically acceptable salts, essentially requiring two separate salts rather than a single complex entity. The court distinguished between a "double salt" (which it characterized as a single salt) and the separate salt components required by the patent claim.
The Full Court also rejected Novartis' argument about solution preparations, finding that a pharmaceutical composition in accordance with claim 1 could be prepared as a solution depending on the choice of appropriate solvent, without changing the fundamental requirement for distinct components.
Market Impact and Regulatory Timeline
The expedited appeal process was driven by regulatory requirements, as the Department of Health had required Pharmacor (搜索) to withdraw its Pharmaceutical Benefits Scheme (PBS) application by March 24, 2025, if the patent dispute remained unresolved.
With Novartis exhausting all appeal avenues - the High Court dismissed the company's special leave application with costs on August 7, 2025 - generic sacubitril/valsartan products from both Pharmacor (搜索) and Apotex (搜索) have now received PBS listing. Novartis has also introduced a secondary brand to compete in the newly opened market.
Broader Patent Law Implications
The decision reinforces Australian courts' strict approach to patent claim construction, emphasizing the importance of giving words their ordinary meaning rather than broadening interpretations through specification references. The ruling demonstrates how precise claim construction can be determinative for both patent infringement and patent term extension validity.
The case highlights the critical importance of aligning patent claims with actual product formulations, particularly for pharmaceutical companies seeking patent term extensions based on regulatory approvals. The court's finding that Entresto itself fell outside the scope of Novartis' own patent claims serves as a cautionary example for pharmaceutical patent strategy.